Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Upstream Bio logo — Developing treatments for inflammatory diseases

Upstream Bio

Developing treatments for inflammatory diseases

Founded 2021 United States Waltham, United States 78 employees IPO Total: $693.00M Biotechnology, Health Care +2

General Information

Company Name Upstream Bio
Founded Year 2021
Location United States Waltham, United States
Employees 78
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage IPO
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Upstream Bio. To contact Upstream Bio, visit upstreambio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Upstream Bio compare?

A PDF of Upstream Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Upstream Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Upstream Bio

Upstream Bio, founded in 2021, is a promising player in the Biotechnology sector with a focus on Health Care and Pharmaceuticals, headquartered in the United States. The company's slogan, "Developing treatments for inflammatory diseases," underscores its mission in the health and wellness arena.

Central to their innovation is verekitug, a clinical-stage monoclonal antibody. This treatment uniquely targets an upstream driver of the inflammatory response, potentially revolutionizing therapeutic options for patients with severe inflammatory diseases. This positioning highlights the company's strategic intent to address significant health challenges.

In a recent financial milestone, Upstream Bio attracted a substantial $293.00M IPO investment as of 01 October 2024. This injection of capital underscores strong investor confidence and positions the company well for advanced research and market penetration.

Business keywords: inflammatory diseases, monoclonal antibody, clinical-stage therapy, vereKitug, immunotherapy, TSLP receptor inhibition, severe asthma, immune cell signaling, pharmaceutical development, upstream immune modulation, chronic disease treatment

Services & Products

Development of verekitug for targeting TSLP in inflammatory diseases
Conducting clinical trials for respiratory disease treatments
Research and innovation in chronic inflammatory diseases

Target Customers

Patients with chronic respiratory diseases Healthcare professionals specializing in respiratory health Researchers and clinicians in the field of inflammatory diseases

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
IPO $293.00M -
01 Oct 2024
Series B $200.00M 12
HBM Healthcare Investments OrbiMed Wellington Management
HBM Healthcare Investments, OrbiMed +10
01 Jun 2023
Series A $200.00M 9
HBM Healthcare Investments OrbiMed Access Biotechnology
HBM Healthcare Investments, OrbiMed +7
01 Jun 2022
Series A Undisclosed 1
HBM Healthcare Investments
HBM Healthcare Investments
01 Oct 2021

Upstream Bio Alternatives & Competitors

View All Alternatives
Upstream Bio vs
Tridek-One
Tridek-One France

We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseases

Venture round
12 employees
Biotechnology, Health Care
Compare Upstream Bio vs Tridek-One
Upstream Bio vs
Zenas BioPharma
Zenas BioPharma United States

Enabling patients with autoimmune diseases to reimagine life

Series C
196 employees
Biopharma, Health Care
Compare Upstream Bio vs Zenas BioPharma
Upstream Bio vs
Calluna Pharma
Calluna Pharma Norway

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the sour...

Series A
27 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Upstream Bio

Developing treatments for inflammatory diseases
Upstream Bio was founded in 2021.
Upstream Bio is headquartered in Waltham, United States.
Upstream Bio operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on inflammatory diseases, monoclonal antibody, clinical-stage therapy and vereKitug. Its customers include Patients with chronic respiratory diseases, Healthcare professionals specializing in respiratory health and Researchers and clinicians in the field of inflammatory diseases.
Upstream Bio has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
Upstream Bio has approximately 78 employees.
Upstream Bio has completed 4 funding rounds, raising a total of $693.00M. The latest funding stage is IPO.
Upstream Bio offers: Development of verekitug for targeting TSLP in inflammatory diseases, Conducting clinical trials for respiratory disease treatments, Research and innovation in chronic inflammatory diseases.
Top alternatives and competitors to Upstream Bio include Tridek-One, Zenas BioPharma, Calluna Pharma, Dianthus Therapeutics, Inc., Mestag Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Upstream Bio and Tridek-One are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Upstream Bio, https://bouncewatch.com/company/upstream-bio, updated 25 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes